Vivos Inc (PK:RDGL)

Business Focus: Medical Imaging Systems

Get the company report for the most recent outlook updated daily

Dec 20, 2023 10:08 am ET

Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation

Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program. Dr....

Aug 07, 2023 09:30 am ET

Vivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinics

Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that it certified three additional clinics to offer Isopet® Precision Radionuclide Therapy (PRT). The three new clinics are The Myhre Equine Clinic, located in Rochester, New Hampshire,...

Jan 11, 2023 09:30 am ET

Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy

Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that the company filed a utility patent application on a range of particles for precision radionuclide therapy as a follow-up to its provisional patent filed on 1/15/2022. This patent was filed in...

Jan 03, 2023 09:30 am ET

Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment

Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a provisional patent application on the system equipment to support precision radionuclide therapy. This includes the shipping containers, the shielded vial holder, the Peltier...

Sep 14, 2022 09:30 am ET

Vivos Inc Files a New Patent on the Hydrogel Component of IsoPet®/RadioGel™

Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a patent application on their hydrogel component of IsoPet/RadioGel in the USA (16309: 17/943,311) and internationally (16389: PCT/US22/43274) under The Patent Cooperation Treaty...

Aug 16, 2022 09:30 am ET

Vivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine Therapy

Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it just certified the New England Equine Practice in Patterson, NY to administer Precision Radionuclide IsoPet® therapy for treating solid tumors in horses. IsoPet® is a next generation...

May 12, 2022 09:30 am ET

Vivos Inc. Provides Intellectual Property Protection Update

Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts. Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries...

Apr 21, 2022 09:30 am ET

Vivos Inc Implements Multiple Patient IsoPet® Therapy Day

Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce a combined IsoPet® therapy schedule into one treatment day, allowing for one production run to provide multiple Isopet® therapies that are done in any one of our current three regional...

Feb 24, 2022 09:30 am ET

Vivos Inc. Enhances its Intellectual Property Protection

Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries. Our new patent team filed the particle patent in the USA, Canada, the European Union, Japan, Australia, Brazil, China, India, South...

Jan 24, 2022 09:30 am ET

Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives

Vivos Inc. (OTCQB: RDGL), provides 2021 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2022, we wanted to review our progress during the past year and provide insights on our thinking for 2022 and beyond.”...

Dec 02, 2021 09:30 am ET

Vivos Inc Obtains Feedback from the FDA on Clinical Testing of RadioGel™

Vivos Inc. (OTCQB: RDGL), on November 30 Vivos Inc met with the Food and Drug Administration to obtain suggestions on improving the current draft of the Investigational Device Exemption, which is necessary to initiate clinical testing in humans....

Nov 23, 2021 09:30 am ET

Vivos Inc Announces Johns Hopkins University (Veterinary Clinical Trials Network) is a New Regional Clinic for Isopet®

Vivos Inc. (OTCQB: RDGL), Vivos Inc announced that Johns Hopkins University VCTN, Veterinary Clinical Trials Network, is now an Isopet® regional clinic. Additionally, Johns Hopkins will also perform new Isopet® animal studies on various specific...

Nov 22, 2021 09:30 am ET

Vivos Inc Announces John Hopkins University as a New Regional Clinic for Isopet®

Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that John Hopkins University Center for Image Guided Animal Therapy (CIGAT) is now an Isopet® regional clinic. Additionally, Johns Hopkins will also perform new Isopet® animal studies on various...

Oct 18, 2021 09:30 am ET

Vivos Inc Signs a MOU for a New Regional Clinic in NY for IsoPet Therapy

Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it signed a Memorandum of Understanding with the Animal Hospital Surgical Center in East Meadow New York on Long Island to become an IsoPet regional therapy center. Vivos Inc is currently...

Sep 22, 2021 09:30 am ET

Vivos Inc Completes Certification Training Modules for Future IsoPet® Therapy Regional Clinics

Vivos Inc. (OTCQB: RDGL), Vivos Inc working with FX Masse completed nine certification training modules that are part of the certification training for new regional clinics. The modules are now on the FX Masse website with a separate unique UR web...

Sep 20, 2021 09:30 am ET

Vivos Inc. Files Early Feasibility IDE Application with FDA for Radiogel™

Vivos Inc. (OTCQB: RDGL), Vivos Inc. is pleased to announce that it has submitted the IDE, Investigational Device Exemption for The Early Feasibility Medical Device Study, First in Human Study for Y-90 RadioGel™, to the Food and Drug Administration...

Jun 24, 2021 09:30 am ET

Vivos Inc Initiates Isopet® Therapy in Horses

Vivos Inc. (OTCQB: RDGL) Vivos Inc announced that it has completed the first IsoPet® therapy on an equoid tumor. It was administered at the University of Missouri on a horse that was transported from Ohio. This is an exciting extension of Isopet®,...

May 27, 2021 09:30 am ET

Vivos Inc. Expands IsoPet® Trademark Protection

Vivos Inc. (OTCQB: RDGL). Vivos Inc. previously filed to extend its IsoPet® trademark protection internationally. We are pleased to report that the Commissioner for Trademarks at the U.S. Patent and Trademark Office has confirmed the filing and...

May 24, 2021 09:30 am ET

Vivos Inc Enhances Radiogel™ Manufacturing Process

Vivos Inc. (OTCQB: RDGL), During the past few months Vivos has made significant enhancements to the manufacturing process for Radiogel™. These enhancements are crucial in aligning with FDA requirements for future clinical trials and licensing to...

Jan 28, 2021 09:30 am ET

Vivos Inc. Provides 2020 Recap and Outlines 2021 Objectives

Vivos Inc. (OTCQB: RDGL), provides 2020 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2021, I think it is important to review our progress during the past year and provide some insight on our goals and...

Jan 19, 2021 09:30 am ET

Vivos Inc Receives Feedback from FDA on Breakthrough Designation Request

Vivos Inc. (OTCQB: RDGL), Although we were unable to secure a Breakthrough Device Designation from the FDA, this was a well-designed process that considerably benefited Vivos Inc and provided us substantive and constructive feedback. We can now...

Dec 09, 2020 09:30 am ET

Vivos Inc Completes Surrogate Lymph Node Testing Using Mouse Spleen Injections Demonstrating Uniform Perfusion and Stability

Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it worked with Mayo Clinic doctors to design and then conduct tests on the injection of hydrogel into spleens in mice. This conservative animal model was designed to gain...

Dec 07, 2020 09:30 am ET

Vivos Inc to Present at The 13th Annual LD Micro Main Event Conference December 15, 2020 11:00 AM Eastern Standard Time

Vivos Inc. (OTCQB: RDGL``), Vivos Inc (RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals and in humans, today announced that it will be presenting at the 13th annual LD...

Dec 01, 2020 09:30 am ET

Vivos Inc Extends it Intellectual Property Protection

Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search Report on our patent application (No.1811.191). We are excited to report that seven of our claims were immediately ruled...

Nov 20, 2020 09:30 am ET

Vivos Inc Applies for Breakthrough Device Designation for Radiogel™

Vivos Inc. (OTCQB: RDGL), Vivos Inc announced that it has completed its submission to the FDA seeking Breakthrough Device Designation for Radiogel™. This is a voluntary program for certain medical devices that provide for more effective...

Sep 03, 2020 09:30 am ET

Vivos Inc Initiates IsoPet Therapy of Horses – Addressing Unmet Need for the Treatment of Equine Tumors

Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet® into the equine market by making IsoPet® available to treat solid tumors in horses. The most common tumors are equoids and sarcomas. This is an important...

Sep 01, 2020 09:30 am ET

Vivos Inc to Present at The LD 500 Virtual Conference

LOS ANGELES, CA / ACCESSWIRE / September 1, 2020 / Vivos Inc (OTCQB:RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals and in humans, today announced that it will be presenting at the LD 500 investor conference on Thursday September 3 at 1:40 PST / 4:00 PM EST. Dr. Mike Korenko (CEO of Vivos Inc) will be presenting to a live virtual audience.

Aug 31, 2020 05:00 pm ET

(LD Micro) 360 Companies Set to Present this Week

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Aug 26, 2020 09:30 am ET

Vivos Inc Provides Update on Initial Indication for Use for RadioGelTM Therapy

Vivos Inc. (OTCQB: RDGL), We are excited to announce that based on the recommendation of our Medical Advisory Board, Vivos Inc has decided on treating inaccessible (non-resectable) cancerous lymph nodes, particularly in the head, neck, and lungs as...

Jul 30, 2020 07:00 am ET

Vivos Inc Reports Additional IsoPet Therapies

Vivos Inc. (OTCQB: RDGL), Interest in IsoPet therapy is increasing. Yesterday Vivos Inc treated “Mister Motto” a cat that the pet parents flew to the state of Washington from New York City. As interest and awareness continues to increase, pet...

Jul 22, 2020 07:00 am ET

Vivos Inc Receives Grant of Protection for RadioGel™ Therapy in China

Vivos Inc. (OTCQB: RDGL), Vivos announced it received the Grant of Protection for the Radiogel™ trademark application in China. The mark is now officially registered in China until April 21, 2024, with the opportunity to extend for an additional 10...

Jun 24, 2020 07:30 am ET

Vivos Inc Achieves Important Radiogel™ Development Milestones

Vivos Inc. (OTCQB: RDGL), Vivos announced today significant progress in its efforts to advance RadioGel™ for human therapy. Animal testing at the University of Missouri was completed in 2019. Since then we have been focusing on completing the...

Jun 10, 2020 07:00 am ET

Vivos Inc Expands its Intellectual Property Protection

Vivos Inc. (OTCQB: RDGL), Vivos announced that is has submitted an international application based on its patent submittal last June. This is part of the Patent Cooperation Treaty (PCT), which cover 153 countries. It allows 30 months for the filing...

May 29, 2020 07:00 am ET

Vivos Inc Resumes IsoPet Animal Cancer Therapy

Vivos Inc. (OTCQB: RDGL), Vivos Inc Resumes IsoPet Animal Cancer Therapy After several months of virus-related stand-down IsoPet therapy has been scheduled for the week of June 20. Our East Coast Y-90 supplier, our Texas production site and...

Feb 06, 2020 07:30 am ET

University of Missouri Becomes the first Regional Clinic for Isopet® Therapy

Vivos Inc. (OTCQB: RDGL), Vivos today announced that the University of Missouri College of Veterinary Medicine will be the first Isopet® regional clinic. The Isopet® therapy will now be included as a treatment option within their extensive...

Jan 13, 2020 07:30 am ET

Vivos Inc. Provides 2019 Recap and Outlines 2020 Objectives

Vivos Inc. (OTCQB: RDGL), provides 2019 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2020, I think it is important to review our progress during past year and to provide some insight on our goals and...

Dec 03, 2019 07:00 am ET

Vivos Inc. Treats Additional Patients at its Pilot Clinic

Vivos Inc. (OTCQB: RDGL) today announced that two dogs with different cancer types were treated using Vivos Inc.’s Isopet® therapy on November 27 at our pilot clinic, Vista Veterinary Hospital in Kennewick, WA. One dog with hemangiosarcoma and...

Oct 22, 2019 07:00 am ET

Vivos Inc. Reports on IsoPet® Therapy at the Veterinary Cancer Society Annual Meeting

Vivos Inc. (OTCQB: RDGL), Vivos, Inc. key personnel attended the Veterinary Cancer Society annual meeting last week in Houston Texas which was attended by nearly 700 veterinary oncology professionals. Vivos was a bronze sponsor at this premier...

Sep 18, 2019 07:00 am ET

Vivos Inc. Announces Listing to the OTCQB

Vivos Inc. (OTCQB: RDGL), Vivos Inc. a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to combat cancer in animals and humans, today announced that its common shares have been approved for...

Jul 29, 2019 07:00 am ET

Vivos Inc. Stock Symbol Reverts to RDGL University of Missouri Report Near Completion

Vivos Inc. (OTCPINK: RDGL), stock symbol reverts back to RDGL effective with the open of trading on Monday, July 29. As previously disclosed, the D at the end of the stock ticker is removed 20 business days following the completion of the reverse...

Jul 11, 2019 07:00 am ET

Vivos Inc. Pilot Clinic Completes First IsoPet® Therapy

Vivos Inc. (OTCPINK: RDGLD), Dr. Michelle Meyers, IsoPet® certified veterinarian practicing at Vista Veterinary Hospital, treated their first patient, a cat named Drake. The patient has already been released since this is same-day therapy....

Jul 09, 2019 07:00 am ET

Vivos Inc. Pilot Clinic Completes Their Certification Training

Vivos Inc. (OTCPINK: RDGLD) Vivos, Inc. is pleased to announce that Vista Veterinary Hospital has completed its first Isopet® certification training for two verterinary professionals, with more expected in the near future. Employee certification...

Jul 02, 2019 07:00 am ET

Vivos Inc. Enhances its Intellectual Property Protection

Vivos Inc. (OTCPINK: RDGLD), Vivos today announced the filing of a patent application covering key aspects of its technology and propriety manufacturing process. Vivos CEO, Dr. Mike Korenko stated “enhancing and extending our intellectual...

Jun 27, 2019 03:07 pm ET

Vivos Inc. Issues Corrective Press Release Regarding Reverse Stock Split

Vivos Inc. (the “Company”) (OTC PINK: RDGL), a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to combat cancer in animals and humans, is issuing this press release to correct its press...

Jun 26, 2019 07:00 am ET

Vivos Inc. Announces 1-for-8 Reverse Stock Split

Vivos Inc. (the “Company”) (OTC PINK: RDGL), a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to combat cancer in animals and humans, today announced that it will effect a 1-for-8 reverse...

Jun 18, 2019 07:00 am ET

IsoPet® Pilot Therapy Clinic Obtains Radioactive Material License

Vivos Inc. (OTCPINK: RDGL), Vista Veterinary Hospital obtained their license to administer IsoPet® for animal therapy from the state of Washington. This license is an important step in our IsoPet® commercialization plan. The next step for...

Apr 30, 2019 07:00 am ET

Vivos Inc. Reports Progress

Vivos Inc. (OTCPINK: RDGL), provides an update on the progress towards commercialization of Y-90 IsoPet® for animal therapy. Animal TestingThis week we will be treating our last dog in the test series for soft tissue sarcoma therapy...

Mar 04, 2019 07:00 am ET

Vivos Inc. Summarizes the Health of Canine Therapy Patients Treated with IsoPet

Vivos, Inc. (OTCPINK: RDGL), provides a summary of the previous update on dogs that have been treated to date in the canine soft tissue sarcoma series. Dr. Mike Korenko, Vivos Inc CEO stated “On February 25, 2019 we provided a detailed update on...

Feb 25, 2019 07:00 am ET

Vivos Inc. Reports on the Health of Canine Therapy Patients

Vivos, Inc. (OTC PINK: RDGL) Vivos Inc. (OTCPINK: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in animals and humans, provides this update on the dogs that were...

Feb 01, 2019 04:05 pm ET

Vivos Inc. Issues Letter to Its Shareholders

Vivos, Inc. (OTC PINK: RDGL). The Board of Directors of Vivos Inc. (OTCPINK: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in animals and humans, addresses its...

Jan 11, 2019 07:00 am ET

Vivos Inc. Announces Expanded Applications of IsoPet® for Veterinary Cancer Therapy

Vivos, Inc. (OTCPINK: RDGL), announced that the device classification obtained from the FDA Center for Veterinary Medicine (CVM) is not limited to canine and feline sarcomas, and can be extended to a much broader population of veterinary...

Jan 09, 2019 07:00 am ET

Vivos Inc 2018 Highlights

Vivos, Inc. (OTC PINK: RDGL) The Board of Directors Reports:In spite of being handcuffed by legacy debt financing, Vivos Inc made considerable progress in 2018. This was largely possible due to the breakthrough nature of the IsoPet® technology....

Dec 04, 2018 03:50 pm ET

Vivos Inc. to Treat Advanced Canine Patient for Soft Tissue Sarcoma with IsoPet®

Vivos, Inc. (OTC PINK: RDGL) a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, has agreed to supply IsoPet® to treat a dog with advanced cancer at the...

Oct 26, 2018 07:00 am ET

Vivos Inc. Successfully Administers IsoPet® to a Second Dog for Canine Sarcoma at the University of Missouri

Vivos, Inc. (OTC PINK: RDGL) Vivos Inc reported that the second dog in a five-dog series was successfully treated yesterday with Y-90 IsoPet® at the University of Missouri. Dr. Charlie Maitz, the University of Missouri veterinarian reported “The...

Oct 22, 2018 07:00 am ET

Vivos Inc. Reports Strong Reception to IsoPet® At Veterinary Cancer Society Conference

Vivos, Inc. (OTC PINK: RDGL) Vivos Inc is pleased to report that its attendance and presentation at the annual meeting of the Veterinary Cancer Society in Louisville, Kentucky was very well received. A significant number of the attendees stopped by...

Oct 10, 2018 07:00 am ET

Vivos, Inc. Completes Common Stock Equity Financing to Fund Roll Out of IsoPet™ and Eliminate Toxic Debt

Vivos, Inc. (OTC PINK: RDGL) Vivos, Inc. a pharmaceutical company researching and developing minimally invasive treatments to combat cancer in humans and animals, announced today, that the company has successfully raised enough funding to...

Oct 02, 2018 07:00 am ET

Vivos Inc Signs Memorandum of Understanding with Private Veterinary Hospital as Pilot Clinic for Commercial IsoPet® Therapy

Vivos Inc (OTC: RDGL) selected its first clinic for commercial sales of IsoPet Vivos Inc., a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, announced today...

Sep 26, 2018 07:00 am ET

First Successful Treatment of Canine Sarcoma using IsoPet® to be Presented at Veterinary Cancer Society Conference

Vivos Inc (OTC PINK: RDGL) first therapy to canine treat soft tissue sarcoma is successful Vivos Inc, a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals,...

Sep 25, 2018 02:15 pm ET

Amending and Replacing the Initial Press Release on George Sharp; Disregard the first release:

Vivos Inc. (OTC: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, today announced that it has retained well-known microcap analyst and consultant,...

Sep 25, 2018 11:12 am ET

Vivos Inc Retains Well-Known Analyst, George Sharp, as Advisor - Updated

Sep 25, 2018 07:00 am ET

Vivos Inc Retains Well-Know OTC Markets Analyst, George Sharp, as Advisor

Vivos Inc. (OTCPINK: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, today announced that it has retained well-known microcap analyst and consultant...

Sep 24, 2018 07:00 am ET

Vivos Inc Signs a Standstill Agreement with Debt Holders Designed to Halt the Toxic Selling and Eliminate the Secured Toxic Debt

Vivos, Inc. (OTC PINK: RDGL) Vivos Inc is pleased to announce that all the debtholders of Vivos’ secured convertible debt have agreed to a ten trading day market standstill, during which time they agree to refrain from any conversions or to...

Sep 21, 2018 05:08 pm ET

Vivos Inc Signs a Standstill Agreement with Debt Holders Designed to Halt the Toxic Selling and Create a Debt Free Company

Vivos, Inc. (OTC PINK: RDGL) Vivos Inc is pleased to announce that all the debtholders of Vivos convertible debt have agreed to a 10 day standstill, during which time they agree not to convert any more debt into common stock as well as not trade...

Aug 02, 2018 06:00 am ET

Vivos Inc Sets the Stage for the Introduction of IsoPet® (RadioGel™) to the Veterinarian Community

Vivos Inc (OTC: RDGL) finalizes its plan to introduce IsoPet® to the veterinarian community. IsoPet® was designated as a device by the FDA and the Center for Veterinary Medicine has reviewed Vivos’ labeling and instructions for use for treating...

Jul 30, 2018 06:00 am ET

Vivos Inc Obtains Trademark Protection for IsoPet®

Vivos Inc (OTC: RDGL) obtains IsoPet trademark protection. The U.S. Patent and Trademark Office (“USPTO”) issued the Certificate of Registration for the mark ISOPET (Reg. No. 5,476,327) in Class 5. Mike Korenko, Vivos CEO says “This is an...

May 31, 2018 06:00 am ET

Vivos Inc Successfully Treats Canine Sarcoma with IsoPet™ (RadioGel™)

Vivos Inc (OTC: RDGL) successfully treated canine soft tissue sarcoma with its proprietary IsoPet™ (RadioGel™), a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. A veterinary cancer...

May 01, 2018 09:00 am ET

Vivos Demonstrates that IsoPet™ (RadioGel™) is effective in killing cancer in cats

Mar 20, 2018 09:30 am ET

Vivos Adds Commercial Expertise to its Veterinary Medicine Advisory Board

Richland, WA, March 20, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it added a new member on the Veterinary Medicine Advisory Board.

Jan 30, 2018 09:00 am ET

Vivos Receives FDA Confirmation of RadioGel Device Classification for Animal Skin Cancer Therapy

Richland, WA, Jan. 30, 2018 (GLOBE NEWSWIRE) --

Jan 12, 2018 11:54 am ET

Vivos Completes Planned Dosing Schedule for Feline Sarcoma Program

Richland, WA, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it has completed its planned dosing schedule to determine the effectiveness of using the Company’s proprietary RadioGel™ therapy to treat feline sarcoma.

Jan 02, 2018 09:00 am ET

Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL

Richland, WA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Advanced Medical Isotope Corporation (OTCPink: RDGL) announced today that it has changed its name to Vivos Inc., and that its shares are scheduled to trade under the new symbol,...

Ad blocking detected

Vivos Inc (PK:RDGL)

Business Focus: Medical Imaging Systems